Effects of Incretin-Based Therapies on Metabolic and Muscular Homeostasis

Advances in understanding how the body regulates metabolism, particularly the role of incretin hormones, have directly led to the development of effective therapies for improving glycemic control and managing weight, particularly for individuals with type 2 diabetes and/or obesity. These medications, such as GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists, mimic or enhance the effects of naturally occurring incretin hormones.

At the 32nd European Congress on Obesity, WuXi Biology presented a poster highlighting a study that evaluated the effects of the GLP-1 agonist semaglutide, the dual-target agonist tirzepatide, and the triple-target agonist retatrutide on glycemic control, weight loss, body composition, and muscle function in a humanized diet-induced obesity mouse model.  The authors show that semaglutide, tirzepatide, and retatrutide significantly reduce body weight and fat mass in this model. Retatrutide showed the most pronounced effects on fat loss in this study, though it slightly compromised muscular function.

ECO 2025 Poster_Effects of Incretin-Based Therapies on Metabolic and Muscular Homeostasis

Download